SHARE NOW
Kyverna Therapeutics has oversubscribed its Series B funding to $145 million, further expanding opportunities for the company to support the development of its novel anti-CD19 CAR T-cell therapies, KYV-101 and KYV-201, for the treatment of B cell-mediated autoimmune diseases.
Clinical-stage cell therapy company, Kyverna Therapeutics, Kyverna, announced the close of an oversubscribed $60 million Series B financing round extension, totaling the Series B financing round to $145 million. Existing investors include Gilead Sciences, Westlake Village BioPartners, Vida Ventures, Northpond Ventures, RTW Investments, Insight Partners, CAM Capital, LYFE Capital, jVen Capital, and others, with new investors Bain Capital Life Sciences and GordonMD® Global Investments LP.
“This Series B extension will fund Kyverna’s clinical studies in the U.S. and Europe, enabling us to move more quickly toward bringing potentially transformative and life-saving therapies to patients,” said Ryan Jones, chief financial officer of Kyverna.
Kyverna’s mission is to engineer a new class of therapies for autoimmune diseases, with its pipeline including next-generation autologous and allogeneic CAR T-cell therapy formats with properties suited for use in B cell-driven autoimmune diseases such as lupus nephritis.
“We are pleased by the increasing investor confidence in the promise of Kyverna’s anti-CD19 CAR T-cell therapy for autoimmune diseases,” commented Jones.
Kyverna’s novel anti-CD19 CAR T-cell therapies, KYV-101 and KYV-201 target the CD19 protein expressed on the surface of B cells, potentially offering new hope to patients who have tried current treatment options but still have unmet clinical needs.
How are you enjoying this news article? Let us know your thoughts, here >>
KYV-101, an autologous version of a novel fully clinical-stage anti-CD19 CAR T-cell construct, demonstrated properties that singled out KYV-101 as a product poised for use in autoimmune disease in a 20-patient oncology Phase I/II study. KYV-101 has initiated a Phase I clinical trial in lupus nephritis in the U.S. and a Phase I/II trial in Germany.
KYV-201 is an allogeneic version of Kyverna’s novel fully clinical-stage anti-CD19 CAR T-cell construct, leveraging the power of genome editing through a propriety ex vivo CRISPR/Cas 9-based allogeneic platform for use in B cell-mediated autoimmune diseases.
Craig Gordon, M.D., founder, CEO, and chief investment officer of Gordon MD® Global Investments LP said:
“I have supported anti-CD19 CAR T-cell therapy for cancer since the early clinical trials. It is exciting to see Kyverna break into new frontiers by advancing cell therapies for autoimmune diseases. I am looking forward to future developments from Kyverna.”
Source: Kyverna Therapeutics Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
